CTOs on the Move

Linnaeus Therapeutics

www.linnaeustx.com

 
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.linnaeustx.com
  • 30 Washington Ave Suite F
    Haddonfield, NJ USA 08033
  • Phone: 856.433.1300

Executives

Name Title Contact Details

Funding

Linnaeus Therapeutics raised $12M on 09/17/2019

Similar Companies

Progenics

Progenics is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keryx

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.

ProtonDx

Because your organisation needs certainty when testing for Covid-19

Medicure

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.

Cima Labs

CIMA Labs Inc. develops and manufactures orally disintegrating tablet and enhanced-absorption oral drug delivery systems. The Company's lead, orally disintegrating tablet technologies, OraSolv and DuraSolv, allow an active drug ingredient, which is